Reevaluation of the 22-1-1 antibody and its putative antigen, EBAG9/RCAS1, as a tumor marker

<p>Abstract</p> <p>Background</p> <p>Tumor-associated antigens are appreciated as diagnostic markers, but they have also prompted tremendous efforts to develop tumor-specific immunotherapy. A previously cloned tumor-associated antigen, EBAG9, was initially defined by re...

Full description

Bibliographic Details
Main Authors: Daniel Peter, Stein Harald, Lehmann Insa, Erdmann Bettina, Anagnostopoulos Ioannis, Reimer Tatiana A, Dörken Bernd, Rehm Armin
Format: Article
Language:English
Published: BMC 2005-05-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/5/47
id doaj-aad4847d69634ea7926df5ea520f9d17
record_format Article
spelling doaj-aad4847d69634ea7926df5ea520f9d172020-11-25T00:18:34ZengBMCBMC Cancer1471-24072005-05-01514710.1186/1471-2407-5-47Reevaluation of the 22-1-1 antibody and its putative antigen, EBAG9/RCAS1, as a tumor markerDaniel PeterStein HaraldLehmann InsaErdmann BettinaAnagnostopoulos IoannisReimer Tatiana ADörken BerndRehm Armin<p>Abstract</p> <p>Background</p> <p>Tumor-associated antigens are appreciated as diagnostic markers, but they have also prompted tremendous efforts to develop tumor-specific immunotherapy. A previously cloned tumor-associated antigen, EBAG9, was initially defined by reactivity with the monoclonal antibody 22-1-1. Functionally, the EBAG9-encoded gene-product was believed to induce apoptosis in activated immune cells. However, using a cell-biological approach we identified EBAG9 as a Golgi-resident modulator of O-linked glycan expression, the latter product was then recognized by the 22-1-1 antibody. Secondly, EBAG9 expression was found physiologically in all murine tissues examined. This raised the question if EBAG9 is tumor-specific and mediates apoptosis itself or through O-linked glycans generated, among them the cognate 22-1-1 antigen Tn.</p> <p>Methods</p> <p>We have used immunohistochemistry to detect the expression of 22-1-1 and EBAG9 in various tissues. Correlation between expression of both antigens in cell lines was analysed by immunoblot and flow cytometry. Apoptosis was studied by using flow cytometry and Caspase-Glo™ 3/7 assay kit. Cellular distribution of EBAG9 was analysed by electron and confocal microscopy.</p> <p>Results</p> <p>Here, we compared expression of the 22-1-1 and EBAG9-defined antigens in normal and neoplastic tissues in situ. In contrast to 22-1-1 staining, EBAG9 is a ubiquitously expressed antigen in all normal and cancerous tissues. Functional studies on the role of 22-1-1 reactive material did not support any evidence for apoptosis induction. Employing electron and confocal microscopy, a refined subcellular localization of EBAG9 at the Golgi was obtained.</p> <p>Conclusion</p> <p>We suggest that the estrogen-inducible EBAG9 gene-product and the 22-1-1 defined antigen are structurally and functionally separate antigens.</p> http://www.biomedcentral.com/1471-2407/5/47
collection DOAJ
language English
format Article
sources DOAJ
author Daniel Peter
Stein Harald
Lehmann Insa
Erdmann Bettina
Anagnostopoulos Ioannis
Reimer Tatiana A
Dörken Bernd
Rehm Armin
spellingShingle Daniel Peter
Stein Harald
Lehmann Insa
Erdmann Bettina
Anagnostopoulos Ioannis
Reimer Tatiana A
Dörken Bernd
Rehm Armin
Reevaluation of the 22-1-1 antibody and its putative antigen, EBAG9/RCAS1, as a tumor marker
BMC Cancer
author_facet Daniel Peter
Stein Harald
Lehmann Insa
Erdmann Bettina
Anagnostopoulos Ioannis
Reimer Tatiana A
Dörken Bernd
Rehm Armin
author_sort Daniel Peter
title Reevaluation of the 22-1-1 antibody and its putative antigen, EBAG9/RCAS1, as a tumor marker
title_short Reevaluation of the 22-1-1 antibody and its putative antigen, EBAG9/RCAS1, as a tumor marker
title_full Reevaluation of the 22-1-1 antibody and its putative antigen, EBAG9/RCAS1, as a tumor marker
title_fullStr Reevaluation of the 22-1-1 antibody and its putative antigen, EBAG9/RCAS1, as a tumor marker
title_full_unstemmed Reevaluation of the 22-1-1 antibody and its putative antigen, EBAG9/RCAS1, as a tumor marker
title_sort reevaluation of the 22-1-1 antibody and its putative antigen, ebag9/rcas1, as a tumor marker
publisher BMC
series BMC Cancer
issn 1471-2407
publishDate 2005-05-01
description <p>Abstract</p> <p>Background</p> <p>Tumor-associated antigens are appreciated as diagnostic markers, but they have also prompted tremendous efforts to develop tumor-specific immunotherapy. A previously cloned tumor-associated antigen, EBAG9, was initially defined by reactivity with the monoclonal antibody 22-1-1. Functionally, the EBAG9-encoded gene-product was believed to induce apoptosis in activated immune cells. However, using a cell-biological approach we identified EBAG9 as a Golgi-resident modulator of O-linked glycan expression, the latter product was then recognized by the 22-1-1 antibody. Secondly, EBAG9 expression was found physiologically in all murine tissues examined. This raised the question if EBAG9 is tumor-specific and mediates apoptosis itself or through O-linked glycans generated, among them the cognate 22-1-1 antigen Tn.</p> <p>Methods</p> <p>We have used immunohistochemistry to detect the expression of 22-1-1 and EBAG9 in various tissues. Correlation between expression of both antigens in cell lines was analysed by immunoblot and flow cytometry. Apoptosis was studied by using flow cytometry and Caspase-Glo™ 3/7 assay kit. Cellular distribution of EBAG9 was analysed by electron and confocal microscopy.</p> <p>Results</p> <p>Here, we compared expression of the 22-1-1 and EBAG9-defined antigens in normal and neoplastic tissues in situ. In contrast to 22-1-1 staining, EBAG9 is a ubiquitously expressed antigen in all normal and cancerous tissues. Functional studies on the role of 22-1-1 reactive material did not support any evidence for apoptosis induction. Employing electron and confocal microscopy, a refined subcellular localization of EBAG9 at the Golgi was obtained.</p> <p>Conclusion</p> <p>We suggest that the estrogen-inducible EBAG9 gene-product and the 22-1-1 defined antigen are structurally and functionally separate antigens.</p>
url http://www.biomedcentral.com/1471-2407/5/47
work_keys_str_mv AT danielpeter reevaluationofthe2211antibodyanditsputativeantigenebag9rcas1asatumormarker
AT steinharald reevaluationofthe2211antibodyanditsputativeantigenebag9rcas1asatumormarker
AT lehmanninsa reevaluationofthe2211antibodyanditsputativeantigenebag9rcas1asatumormarker
AT erdmannbettina reevaluationofthe2211antibodyanditsputativeantigenebag9rcas1asatumormarker
AT anagnostopoulosioannis reevaluationofthe2211antibodyanditsputativeantigenebag9rcas1asatumormarker
AT reimertatianaa reevaluationofthe2211antibodyanditsputativeantigenebag9rcas1asatumormarker
AT dorkenbernd reevaluationofthe2211antibodyanditsputativeantigenebag9rcas1asatumormarker
AT rehmarmin reevaluationofthe2211antibodyanditsputativeantigenebag9rcas1asatumormarker
_version_ 1725375783468269568